Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Go back to Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 5.88 +0.45 (8.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.43 | 52 Week High | $45.34 | |||
| Open | $5.44 | 52 Week Low | $15.92 | |||
| Day High | $5.90 | P/E | 2.52 | |||
| Day Low | $5.34 | EPS | $2.33 | |||
| Volume | 5,205,837 | |||||
